Insmed Inc (INSM)vsSurrozen Inc (SRZN)
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
SRZN
Surrozen Inc
$25.00
-0.95%
HEALTHCARE · Cap: $215.57M
Smart Verdict
WallStSmart Research — data-driven comparison
Insmed Inc generates 16726% more annual revenue ($606.42M vs $3.60M). SRZN leads profitability with a 0.0% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).
INSM
Hold39
out of 100
Grade: F
SRZN
Avoid24
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Conservative balance sheet, low leverage
Areas to Watch
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bull Case : SRZN
The strongest argument for SRZN centers on Debt/Equity.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Bear Case : SRZN
The primary concerns for SRZN are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
INSM profiles as a turnaround stock while SRZN is a value play — different risk/reward profiles.
INSM carries more volatility with a beta of 1.17 — expect wider price swings.
INSM is growing revenue faster at 1.5% — sustainability is the question.
SRZN generates stronger free cash flow (-6M), providing more financial flexibility.
Bottom Line
INSM scores higher overall (39/100 vs 24/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Surrozen Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Surrozen Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics to address severe diseases, leveraging its proprietary SIRPa-IgG platform for targeted immune response modulation. The company's robust pipeline includes groundbreaking antibody therapeutics primarily aimed at oncology and autoimmune disorders, reflecting its commitment to fulfilling significant unmet medical needs. Bolstered by strategic partnerships and a strong emphasis on research and development, Surrozen is strategically positioned to advance transformative therapies, marking it as a promising player within the biopharmaceutical landscape with substantial growth potential.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?